Autologous immune enhancement therapy

Last updated

Autologous immune enhancement therapy
Specialty immunology/oncology

Autologous immune enhancement therapy (AIET) is a treatment method in which immune cells are taken out from the patient's body which are cultured and processed to activate them until their resistance to cancer is strengthened and then the cells are put back in the body. The cells, antibodies, and organs of the immune system work to protect and defend the body against not only tumor cells but also bacteria or viruses.

Contents

Cell division in any living organism is an integral part of life, as worn out cells have to be replaced by newly generated cells. This process of generating new cells varies between organs and the mechanisms involved are highly complex which include the nature and capability of the underlying stem cells, their environment, metabolism, physical and allied biological factors the organ or tissue is subjected to etc., Aberrant cell division takes place that ends up in a cancer cell and such aberrance may be due to faulty stem cell, abnormal genetic components or any other factor such as radiation or a constant irritation. Cancer is still a leading cause of death in the world yet much is still not known about its mechanisms of establishment and destruction. While surgery and/or chemo- and radiotherapies are various treatment modalities available, still in many cases they don't offer a permanent cure. Another major point to be addressed about this killer disease is the relapse rate which is very high.

Researchers have found that these cells mainly target the cancer cells and not the healthy cells whereas in chemotherapy and radiotherapy the healthy cells are also getting destroyed.

Mechanism of action

Cancer cells are formed in our body almost every day but we are not affected by them. This is because they are immediately destroyed by the body's immune system. The immune system is a complex network of cells and organs comprising lymphocytes, macrophages, Dendritic cells, Natural Killer cells (NK Cell), Cytotoxic T Lymphocytes (CTL), etc., that work together to defend the body against attacks by "foreign" or "non-self" invaders including cancer cells. Immediately after a cancer cell is recognized, the Lymphocytes and/or the NK cells attack the cancer cell to kill it. When the immune system is weaker then cancer evolves as a disease and starts growing.

Each type of cancer needs a specific combination of treatments aimed at that particular kind of cancer. When the extent of spread of cancer is deep, total removal of the cancer growth by surgery may not be possible. At times, after surgical removal of a part of the cancer, radiotherapy and/or chemotherapy may be necessary to treat the remnant portion of cancer. It is widely known that Chemotherapy has profound toxic side effects and has limitations in efficacy. Radiotherapy is also a very effective mode of treatment in certain types of cancer, but it has its own adverse effects as well. These two modalities affect not only the cancer affected cells, but also the normal cells

Now in AIET, specific types of cells mainly the NK cells and T lymphocytes are isolated from the peripheral blood of the cancer patients (during remission in patients who undergo chemotherapy) by proven methods, expanded to 25–30 fold and activated and then reinfused back into the patient's body. These cells act against the cancer cells effectively and recharge the immune system. Upon encountering a tumor cell, the activated NK cell attaches to the membrane of the cancer cell and injects toxic granules which dissolve the target cell. In less than five minutes, the cancer cell dies and the NK cell moves on to its next target cancer cell. A single NK cell can destroy up to 27 cancer cells within its lifespan. This is the mechanism by which AIET is effective in cancer therapy.

History

Adoptive Immuno cell therapy of cancer was first introduced by Steven Rosenberg and his colleagues of National Institute of Health USA. In the late 80s, they published an article in which they reported a low tumor regression rate (2.6–3.3%) in 1205 patients with metastatic cancer who underwent different types of active specific immunotherapy (ASI), and they suggest that AIET with specific chemotherapy or radiotherapy as the future of cancer immunotherapy. [1] In the beginning Immunotherapy treatments involved administration of cytokines such as Interleukin. [2] with an aim of inducing the lymphocytes which will carry their activity of destroying the tumour cells. Thereafter the adverse effects of such intravenously administered cytokines [3] lead to the extraction of the lymphocytes from the blood and culture-expand them in the lab and then to inject the cells alone enable them destroy the cancer cells. [4] Till date different kinds of autologous and allogenic immune cells such as lymphokine-activated killer(LAK)cells, Natural killer (NK) cells, Activated Cytotoxic T lymphocytes(CTLs), Dendritic cells(DCs), Gene manipulated autologous and allogenic Immune cells have been used in clinical applications of Immunotherapy.

The present technology of AIET was developed by Japanese scientists and it is being widely practised in several Asian countries which uses autologous natural killer (NK) cells and activated T lymphocytes to treat various cancers.

This treatment modality has been in practice since early 90s and has several random clinical trials in lung cancer, gastric cancer, Ovarian cancer and Liver cancer. [3] which has been published with significant disease free survival rates. One of the largest studies in 1400 patients. [3] has proven that the cell based immunotherapy when combined with conventional treatment the efficacy improves by 20–30%. A recent finding published about a relapsed stage IV ovarian cancer [5] treated successfully with this methodology has found its place in the Global medical discovery. [6]

Status of immunotherapy worldwide

Though the concept of this treatment started in the US in 1980s, full-fledged clinical treatments on a routine basis have been in practice in Japan since 1990. Randomized controlled studies in different cancers with significant increase in survival and disease free period have been reported. [7] [8] [9] [10] In India immunotherapy has shown positive results in patients with advanced cancer including acute myeloid leukaemia, [11] pancreatic cancer, [12] cervical cancer, [13] ovarian cancer, [5] [14] Breast Cancer [15] and Philadelphia chromosome Positive Acute Lymphoblastic Leukemia. [16] [17]

Relevance to Auto-Immune Diseases

Auto-Immune diseases like the Auto-Immune Hemolytic Anemia (AIHA) have been known to be associated with malignancies. In general lower Natural Killer (NK) profile has been associated with development of cancers by earlier studies. [18] Recently an article has been published in which it has been described that the in vitro expansion of NK cells is decreased in cancer patients who have concomitant Auto-immune Diseases like the AIHA. [19] This study also throws questions on whether AIHA is a complication of malignancies, due to the lower NK cell profile in cancer which would have given rise to the AIHA due to some common antibody between NK cells and Red Blood Cells (RBCs) or whether the AIHA lowers the NK cell profile which in turn causes the cancer. This warrants further investigations into the identification of common antibodies between NK cells & RBCs and also finding new Immuno- therapeutic strategies which can tackle both cancer and auto-immunity

Related Research Articles

<span class="mw-page-title-main">Natural killer cell</span> Type of cytotoxic lymphocyte

Natural killer cells, also known as NK cells or large granular lymphocytes (LGL), are a type of cytotoxic lymphocyte critical to the innate immune system. They belong to the rapidly expanding family of known innate lymphoid cells (ILC) and represent 5–20% of all circulating lymphocytes in humans. The role of NK cells is analogous to that of cytotoxic T cells in the vertebrate adaptive immune response. NK cells provide rapid responses to virus-infected cells, stressed cells, tumor cells, and other intracellular pathogens based on signals from several activating and inhibitory receptors. Most immune cells detect the antigen presented on major histocompatibility complex I (MHC-I) on infected cell surfaces, but NK cells can recognize and kill stressed cells in the absence of antibodies and MHC, allowing for a much faster immune reaction. They were named "natural killers" because of the notion that they do not require activation to kill cells that are missing "self" markers of MHC class I. This role is especially important because harmful cells that are missing MHC I markers cannot be detected and destroyed by other immune cells, such as T lymphocyte cells.

Immunotherapy or biological therapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies. Immunotherapy is under preliminary research for its potential to treat various forms of cancer.

A cancer vaccine, or oncovaccine, is a vaccine that either treats existing cancer or prevents development of cancer. Vaccines that treat existing cancer are known as therapeutic cancer vaccines or tumor antigen vaccines. Some of the vaccines are "autologous", being prepared from samples taken from the patient, and are specific to that patient.

<span class="mw-page-title-main">Cancer immunotherapy</span> Artificial stimulation of the immune system to treat cancer

Cancer immunotherapy (immuno-oncotherapy) is the stimulation of the immune system to treat cancer, improving the immune system's natural ability to fight the disease. It is an application of the fundamental research of cancer immunology (immuno-oncology) and a growing subspecialty of oncology.

Lymphoid leukemias are a group of leukemias affecting circulating lymphocytes, a type of white blood cell. The lymphocytic leukemias are closely related to lymphomas of the lymphocytes, to the point that some of them are unitary disease entities that can be called by either name. Such diseases are all lymphoproliferative disorders. Most lymphoid leukemias involve a particular subtype of lymphocytes, the B cells.

<span class="mw-page-title-main">Steven Rosenberg</span> American cancer researcher

Steven A. Rosenberg is an American cancer researcher and surgeon, chief of Surgery at the National Cancer Institute in Bethesda, Maryland and a Professor of Surgery at the Uniformed Services University of Health Sciences and the George Washington University School of Medicine and Health Sciences. He pioneered the development of immunotherapy that has resulted in the first effective immunotherapies and the development of gene therapy. He is the first researcher to successfully insert foreign genes into humans.

<span class="mw-page-title-main">Ipilimumab</span> Pharmaceutical drug

Ipilimumab, sold under the brand name Yervoy, is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.

In cell biology, a lymphokine-activated killer cell is a white blood cell, consisting mostly of natural killer, natural killer T, and T cells that has been stimulated to kill tumor cells, but because of the function in which they activate, and the cells they can successfully target, they are classified as different than the classical natural killer and T lymphocyte systems.

<span class="mw-page-title-main">Cancer immunology</span> Study of the role of the immune system in cancer

Cancer immunology (immuno-oncology) is an interdisciplinary branch of biology and a sub-discipline of immunology that is concerned with understanding the role of the immune system in the progression and development of cancer; the most well known application is cancer immunotherapy, which utilises the immune system as a treatment for cancer. Cancer immunosurveillance and immunoediting are based on protection against development of tumors in animal systems and (ii) identification of targets for immune recognition of human cancer.

<span class="mw-page-title-main">Tumor-infiltrating lymphocytes</span>

Tumor-infiltrating lymphocytes (TIL) are white blood cells that have left the bloodstream and migrated towards a tumor. They include T cells and B cells and are part of the larger category of ‘tumor-infiltrating immune cells’ which consist of both mononuclear and polymorphonuclear immune cells, in variable proportions. Their abundance varies with tumor type and stage and in some cases relates to disease prognosis.

Immunotransplant is a maneuver used to make vaccines more powerful. It refers to the process of infusing vaccine-primed T lymphocytes into lymphodepleted recipients for the purpose of enhancing the proliferation and function of those T cells and increasing immune protection induced by that vaccine.

<span class="mw-page-title-main">Cancer treatment</span> Overview of various treatment possibilities for cancer

Cancer treatments are a wide range of treatments available for the many different types of cancer, with each cancer type needing its own specific treatment. Treatments can include surgery, chemotherapy, radiation therapy, hormonal therapy, targeted therapy including small-molecule drugs or monoclonal antibodies, and PARP inhibitors such as olaparib. Other therapies include hyperthermia, immunotherapy, photodynamic therapy, and stem-cell therapy. Most commonly cancer treatment involves a series of separate therapies such as chemotherapy before surgery. Angiogenesis inhibitors are sometimes used to enhance the effects of immunotherapies.

Adoptive cell transfer (ACT) is the transfer of cells into a patient. The cells may have originated from the patient or from another individual. The cells are most commonly derived from the immune system with the goal of improving immune functionality and characteristics. In autologous cancer immunotherapy, T cells are extracted from the patient, genetically modified and cultured in vitro and returned to the same patient. Comparatively, allogeneic therapies involve cells isolated and expanded from a donor separate from the patient receiving the cells.

Pelareorep is a proprietary isolate of the unmodified human reovirus being developed as a systemically administered immuno-oncological viral agent for the treatment of solid tumors and hematological malignancies. Pelareorep is an oncolytic virus, which means that it preferentially lyses cancer cells. Pelareorep also promotes an inflamed tumor phenotype through innate and adaptive immune responses. Preliminary clinical trials indicate that it may have anti-cancer effects across a variety of cancer types when administered alone and in combination with other cancer therapies.

<span class="mw-page-title-main">Abscopal effect</span> Hypothesis in the treatment of metastatic cancer

The abscopal effect is a hypothesis in the treatment of metastatic cancer whereby shrinkage of untreated tumors occurs concurrently with shrinkage of tumors within the scope of the localized treatment. R.H. Mole proposed the term “abscopal” in 1953 to refer to effects of ionizing radiation “at a distance from the irradiated volume but within the same organism.”

ALECSAT technology is a novel method of epigenetic cancer immunotherapy being used by the company CytoVac. It uses a patient's own immune system to target tumor cells in prostate cancer, glioblastomas, and potentially pancreatic cancer. ALECSAT research, directed by Alexei Kirken and Karine Dzhandzhugazyan, has led to several clinical trials.

The NK-92 cell line is an immortalised cell line that has the characteristics of a type of immune cell found in human blood called ’natural killer’ (NK) cells. Blood NK cells and NK-92 cells recognize and attack cancer cells as well as cells that have been infected with a virus, bacteria, or fungus. NK-92 cells were first isolated in 1992 in the laboratory of Hans Klingemann at the British Columbia Cancer Agency in Vancouver, Canada, from a patient who had a rare NK cell non-Hodgkin-lymphoma. These cells were subsequently developed into a continuously growing cell line. NK-92 cells are distinguished by their suitability for expansion to large numbers, ability to consistently kill cancer cells and testing in clinical trials. When NK-92 cells recognize a cancerous or infected cell, they secrete perforin that opens holes into the diseased cells and releases granzymes that kill the target cells. NK-92 cells are also capable of producing cytokines such as tumor necrosis factor alpha (TNF-a) and interferon gamma (IFN-y), which stimulates proliferation and activation of other immune cells.

Cytokine-induced killer cells (CIK) cells are a group of immune effector cells featuring a mixed T- and natural killer (NK) cell-like phenotype. They are generated by ex vivo incubation of human peripheral blood mononuclear cells (PBMC) or cord blood mononuclear cells with interferon-gamma (IFN-γ), anti-CD3 antibody, recombinant human interleukin (IL)-1 and recombinant human interleukin (IL)-2.

Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus (VACV), a stable DNA virus with a large engineering capacity.

<span class="mw-page-title-main">Cellular adoptive immunotherapy</span> Cellular adoptive immunotherapy

Cellular adoptive immunotherapy is a type of immunotherapy. Immune cells such as T-cells are usually isolated from patients for expansion or engineering purposes and reinfused back into patients to fight diseases using their own immune system. A major application of cellular adoptive therapy is cancer treatment, as the immune system plays a vital role in the development and growth of cancer. The primary types of cellular adoptive immunotherapies are T cell therapies. Other therapies include CAR-T therapy, CAR-NK therapy, macrophage-based immunotherapy and dendritic cell therapy.

References

  1. ↑ Rosenberg SA (January 1984). "Adoptive immunotherapy of cancer: accomplishments and prospects". Cancer Treat Rep. 68 (1): 233–55. PMID   6362866.
  2. ↑ Yang Q, Hokland ME, Bryant JL, et al. (July 2003). "Tumor-localization by adoptively transferred, interleukin-2-activated NK cells leads to destruction of well-established lung metastases". Int. J. Cancer. 105 (4): 512–9. doi:10.1002/ijc.11119. PMID   12712443. S2CID   25325594.
  3. 1 2 3 Egawa K (2004). "Immuno-cell therapy of cancer in Japan". Anticancer Res. 24 (5C): 3321–6. PMID   15515427.
  4. ↑ Kunishima S, Matsushita T, Shiratsuchi M, et al. (January 2005). "Detection of unique neutrophil non-muscle myosin heavy chain-A localization by immunofluorescence analysis in MYH9 disorder presented with macrothrombocytopenia without leukocyte inclusions and deafness". Eur. J. Haematol. 74 (1): 1–5. doi:10.1111/j.1600-0609.2004.00328.x. PMID   15613099. S2CID   20398097.
  5. 1 2 Manjunath, Sadananda Rao; Ramanan, Ganapathi; Dedeepiya, Vidyasagar Devaprasad; Terunuma, Hiroshi; Deng, Xuewen; Baskar, Subramani; Senthilkumar, Rajappa; Thamaraikannan, Paramasivam; Srinivasan, Thangavelu; Preethy, Senthilkumar; Abraham, Samuel J.K. (2012). "Autologous immune enhancement therapy in recurrent ovarian cancer with metastases; 18 months follow-up- A case report". Case Reports in Oncology. 5 (1): 114–118. doi:10.1159/000337319. PMC   3364094 . PMID   22666198.
  6. ↑ "Autologous immune enhancement therapy in recurrent ovarian cancer with metastases: a case report-Global Medical Discovery key scientific article". Archived from the original on 16 November 2012. Retrieved 30 August 2012.
  7. ↑ Fujita K, Ikarashi H, Takakuwa K, et al. (May 1995). "Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes". Clin. Cancer Res. 1 (5): 501–7. PMID   9816009.
  8. ↑ Kimura H, Yamaguchi Y (July 1997). "A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma". Cancer. 80 (1): 42–9. doi:10.1002/(SICI)1097-0142(19970701)80:1<42::AID-CNCR6>3.0.CO;2-H. PMID   9210707.
  9. ↑ Takayama T, Sekine T, Makuuchi M, et al. (September 2000). "Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial". Lancet. 356 (9232): 802–7. doi:10.1016/S0140-6736(00)02654-4. PMID   11022927. S2CID   19241915.
  10. ↑ Kono K, Takahashi A, Ichihara F, et al. (June 2002). "Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial". Clin. Cancer Res. 8 (6): 1767–71. PMID   12060615.
  11. ↑ "Proceedings of the Annual Symposium on Regenerative Medicine(PASRM)". Journal of Stem Cells and Regenerative Medicine. 1 (1): 40–56. 26 December 2006. doi:10.46582/jsrm.0101007. PMC   3907960 . PMID   24692861.
  12. ↑ Abraham, SJK; Baskar, S; Dedeepiya, VD; Terunuma, H; Manjunath, SR; Senthilkumar, R; Sivaraman, G; Pandian, A (2015). "Prolonged survival of a patient with inoperable, locally advanced adenocarcinoma of pancreas after autologous immune enhancement therapy with chemotherapy". Indian Journal of Cancer. 52 (3). Medknow: 395. doi: 10.4103/0019-509x.176721 . ISSN   0019-509X.
  13. ↑ Sumana Premkumar; Vidyasagar Devaprasad Dedeepiya; Hiroshi Terunuma; Rajappa Senthilkumar; Thangavelu Srinivasan; Helen C. Reena; Senthilkumar Preethy; Samuel JK Abraham (2013). "Cell based Autologous Immune Enhancement Therapy (AIET) after radiotherapy in a locally advanced carcinoma of the cervix". Case Reports in Oncological Medicine. 2013: 1–3. doi: 10.1155/2013/903094 . PMC   3638504 . PMID   23653878.
  14. ↑ "Ovarian Cancer treated with Immunotherapy". ::NCRM:: Press Release. 4 May 2011. Retrieved 29 June 2024.
  15. ↑ Chidambaram, Ranganathan; Terunuma, Hiroshi; Balamurugan, Madasamy; Dedeepiya, Vidyasagar Devaprasad; Sumana, Premkumar; Senthilkumar, Rajappa; Rajmohan, Mathaiyan; Karthick, Ramalingam; Preethy, Senthilkumar; Abraham, Samuel J.K. (19 July 2017). "Cell-based immunotherapy in stage IIIA inflammatory breast cancer with declining innate immunity following successive chemotherapies: A case report". Molecular and Clinical Oncology. 7 (3). Spandidos Publications: 493–497. doi:10.3892/mco.2017.1333. ISSN   2049-9450.
  16. ↑ Revathi Raj; M. Deenadayalan; G. Vimal Kumar; Vipin Khandelwal; Karuna Sri; Rajappa Senthilkumar; Samuel J. K. Abraham; Terunuma Hiroshi (2014). "Autologous Immune Enhancement Therapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia". Journal of Hematology and Blood Transfusion. 30 (Suppl 1): 202–204. doi:10.1007/s12288-013-0327-3. PMC   4192214 . PMID   25332578.
  17. ↑ "Blood cancer (Ph+ve Acute Lymphoblastic Leukemia) efficiently tackled in combination with AIET by NCRM". : NCRM : : Nichi-In Centre for Regenerative Medicine(NCRM), Chennai, India An Indo-Japan venture on stem cell therapeutics tissue engineering,FEAT,Fujio-Eiji Academic Terrain, stem cells PhD, TPRM courses. 1 March 2014. Retrieved 29 June 2024.
  18. ↑ Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K (November 2000). "Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population". Lancet. 356 (9244): 1795–9. doi:10.1016/S0140-6736(00)03231-1. PMID   11117911. S2CID   22918838.
  19. ↑ Vidyasagar Devaprasad Dedeepiya; Hiroshi Terunuma; Xuewen Deng; Subramani Baskar; Sadananda Rao Manjunath; Rajappa Senthilkumar; Palanisamy Murugan; Paramasivam Thamaraikannan; Thangavelu Srinivasan; Senthilkumar Preethy; Samuel J.K. Abraham (February 2012). "A comparative analysis of in vitro expansion of natural killer cells of a patient with autoimmune haemolytic anaemia and ovarian cancer with patients with other solid tumours". Oncology Letters. 3 (2): 435–440. doi:10.3892/ol.2011.498. PMC   3362377 . PMID   22740927.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.